NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.42x

NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Reinvestment Rate of 0.42x as of December 2025, reinvesting €13.66 Million (capex €48.00K plus investments €-13.62 Million) from operating cash flow of €32.35 Million. Check NEWRON PHARMACEUT. EO-20 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.42x

(Capex + Investments) / Operating CF

Total Reinvested

€13.66 Million

Capex + Investments

Operating Cash Flow

€32.35 Million

EUR

Capital Expenditures

€48.00K

EUR

NEWRON PHARMACEUT. EO-20 Cash Flow Reinvestment Rate (2025–2025)

Historical reinvestment intensity for NEWRON PHARMACEUT. EO-20 across 1 annual periods. Explore NP5 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for NEWRON PHARMACEUT. EO-20 (2025–2025)

Year-by-year capital reinvestment analysis for NEWRON PHARMACEUT. EO-20. For live market cap and broader valuation context, see NEWRON PHARMACEUT. EO-20 market cap and net worth.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2025	0.42x	€13.66 Million	€32.35 Million	€48.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow